{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:36Z","timestamp":1794893616675,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The phase\u20093 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplantation) (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03391466\">NCT03391466<\/jats:ext-link>\n                    ). Here, we present a prespecified exploratory analysis examining the association between pretreatment tumor characteristics and the efficacy of axi-cel versus SOC. B cell gene expression signature (GES) and CD19 expression associated significantly with improved event-free survival for axi-cel (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0002 for B cell GES;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0165 for CD19 expression) but not SOC (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.9374 for B cell GES;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.5526 for CD19 expression). Axi-cel showed superior event-free survival over SOC irrespective of B cell GES and CD19 expression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20098.56\u2009\u00d7\u200910\n                    <jats:sup>\u20139<\/jats:sup>\n                    for B cell GES high;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0019 for B cell GES low;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20093.85\u2009\u00d7\u200910\n                    <jats:sup>\u20139<\/jats:sup>\n                    for CD19 gene high;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0017 for CD19 gene low). Low CD19 expression in malignant cells correlated with a tumor GES consisting of immune-suppressive stromal and myeloid genes, highlighting the inter-relation between malignant cell features and immune contexture substantially impacting axi-cel outcomes. Tumor burden, lactate dehydrogenase and cell-of-origin impacted SOC more than axi-cel outcomes. T cell activation and B cell GES, which are associated with improved axi-cel outcome, decreased with increasing lines of therapy. These data highlight differences in resistance mechanisms to axi-cel and SOC and support earlier intervention with axi-cel.\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02754-1","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T06:02:53Z","timestamp":1705471373000},"page":"507-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Filosto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saran","family":"Vardhanabhuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Perbost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"Greinix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Budka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M.","family":"Marincola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Mattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bedognetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Galon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"2754_CR1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2754_CR2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.path.2019.03.012","volume":"12","author":"A Chan","year":"2019","unstructured":"Chan, A. & Dogan, A. Prognostic and predictive biomarkers in diffuse large B-cell lymphoma. Surg. Pathol. Clin. 12, 699\u2013707 (2019).","journal-title":"Surg. Pathol. Clin."},{"key":"2754_CR3","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-014-2115-z","volume":"93","author":"JH Park","year":"2014","unstructured":"Park, J. H. et al. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab. Ann. Hematol. 93, 1755\u20131764 (2014).","journal-title":"Ann. Hematol."},{"key":"2754_CR4","doi-asserted-by":"crossref","first-page":"e10576","DOI":"10.15252\/emmm.201910576","volume":"11","author":"H Hashwah","year":"2019","unstructured":"Hashwah, H. et al. The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma. EMBO Mol. Med. 11, e10576 (2019).","journal-title":"EMBO Mol. Med."},{"key":"2754_CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2014.277","volume":"111","author":"KT Troppan","year":"2014","unstructured":"Troppan, K. T. et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. Br. J. Cancer 111, 55\u201360 (2014).","journal-title":"Br. J. Cancer"},{"key":"2754_CR6","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"2754_CR7","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145\u20132154 (2022).","journal-title":"Nat. Med."},{"key":"2754_CR8","first-page":"349","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge, W. A. et al. GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349\u2013358 (2022).","journal-title":"Blood"},{"key":"2754_CR9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","volume":"58","author":"P Dreger","year":"2022","unstructured":"Dreger, P. et al. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience. Bone Marrow Transplant. 58, 229\u2013232 (2022).","journal-title":"Bone Marrow Transplant."},{"key":"2754_CR10","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"2754_CR11","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137, 2621\u20132633 (2021).","journal-title":"Blood"},{"key":"2754_CR12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2021-148605","volume":"138","author":"MD Jain","year":"2021","unstructured":"Jain, M. D. et al. Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapy. Blood 138, 42 (2021).","journal-title":"Blood"},{"key":"2754_CR13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/bloodadvances.2021006845","volume":"7","author":"H Shi","year":"2022","unstructured":"Shi, H. et al. Genetic landscapes and curative effect of CAR T-cell immunotherapy in relapse and refractory DLBCL patients. Blood Adv. 7, 1070\u20131075 (2022).","journal-title":"Blood Adv."},{"key":"2754_CR14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1189\/jlb.1107773","volume":"84","author":"F Pag\u00e8s","year":"2008","unstructured":"Pag\u00e8s, F., Galon, J. & Fridman, W. H. The essential role of the in situ immune reaction in human colorectal cancer. J. Leukoc. Biol. 84, 981\u2013987 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"2754_CR15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00281-011-0264-x","volume":"33","author":"G Bindea","year":"2011","unstructured":"Bindea, G., Mlecnik, B., Fridman, W. H. & Galon, J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin. Immunopathol. 33, 335\u2013340 (2011).","journal-title":"Semin. Immunopathol."},{"key":"2754_CR16","volume":"11","author":"PA Ascierto","year":"2013","unstructured":"Ascierto, P. A. et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J. Transl. Med. 11, 54 (2013).","journal-title":"J. Transl. Med."},{"key":"2754_CR17","doi-asserted-by":"crossref","first-page":"e27456","DOI":"10.4161\/onci.27456","volume":"3","author":"G Bindea","year":"2014","unstructured":"Bindea, G., Mlecnik, B., Angell, H. K. & Galon, J. The immune landscape of human tumors: implications for cancer immunotherapy. Oncoimmunology 3, e27456 (2014).","journal-title":"Oncoimmunology"},{"key":"2754_CR18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni, D., Angell, H. K. & Galon, J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat. Rev. Cancer 20, 662\u2013680 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2754_CR19","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2022-CT004","volume":"82","author":"S Filosto","year":"2022","unstructured":"Filosto, S. et al. Abstract CT004: product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma. Cancer Res. 82, CT004 (2022).","journal-title":"Cancer Res."},{"key":"2754_CR20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"13","author":"JR Westin","year":"2023","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 13, 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2754_CR21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/intimm\/dxn075","volume":"20","author":"R Okada","year":"2008","unstructured":"Okada, R., Kondo, T., Matsuki, F., Takata, H. & Takiguchi, M. Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int. Immunol. 20, 1189\u20131199 (2008).","journal-title":"Int. Immunol."},{"key":"2754_CR22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu, Y. & Barta, S. K. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 94, 604\u2013616 (2019).","journal-title":"Am. J. Hematol."},{"key":"2754_CR23","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313\u20132323 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2754_CR24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/cancers10060194","volume":"10","author":"A Dahmani","year":"2018","unstructured":"Dahmani, A. & Delisle, J. S. TGF-\u03b2 in T cell biology: implications for cancer immunotherapy. Cancers (Basel) 10, 194 (2018).","journal-title":"Cancers (Basel)"},{"key":"2754_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51\u201372 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"2754_CR26","first-page":"1832","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137, 1832\u20131835 (2021).","journal-title":"Blood"},{"key":"2754_CR27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"2754_CR28","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald, A. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937\u20131947 (2002).","journal-title":"N. Engl. J. Med."},{"key":"2754_CR29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"2754_CR30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes, A. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol. 37, 1285\u20131295 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2754_CR31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov, N. et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 11, 1468\u20131489 (2021).","journal-title":"Cancer Discov."},{"key":"2754_CR32","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen, C. B. et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39, 1422\u20131437 e1410 (2021).","journal-title":"Cancer Cell"},{"key":"2754_CR33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright, G. W. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37, 551\u2013568.e514 (2020).","journal-title":"Cancer Cell"},{"key":"2754_CR34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder, B. J. et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41, 210\u2013225.e215 (2023).","journal-title":"Cancer Cell"},{"key":"2754_CR35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2012-12-472027","volume":"122","author":"MJ Matasar","year":"2013","unstructured":"Matasar, M. J. et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 122, 499\u2013506 (2013).","journal-title":"Blood"},{"key":"2754_CR36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28, 735\u2013742 (2022).","journal-title":"Nat. Med."},{"key":"2754_CR37","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","volume":"4","author":"EA Dean","year":"2020","unstructured":"Dean, E. A. et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 3268\u20133276 (2020).","journal-title":"Blood Adv."},{"key":"2754_CR38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2022-158492","volume":"140","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Association of metabolic tumor volume (MTV) and clinical outcomes in second-line (2L) relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL) following axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in ZUMA-7. Blood 140, 638\u2013640 (2022).","journal-title":"Blood"},{"key":"2754_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.immuni.2019.12.018","volume":"52","author":"J Galon","year":"2020","unstructured":"Galon, J. & Bruni, D. Tumor immunology and tumor evolution: intertwined histories. Immunity 52, 55\u201381 (2020).","journal-title":"Immunity"},{"key":"2754_CR40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"2754_CR41","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2754_CR42","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","volume":"138","author":"V Plaks","year":"2021","unstructured":"Plaks, V. et al. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood 138, 1081\u20131085 (2021).","journal-title":"Blood"},{"key":"2754_CR43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579\u2013586 (2007).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02754-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02754-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:14:16Z","timestamp":1708416856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02754-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2754"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02754-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: F.L.L. reports a consulting or advisory role for Allogene, Amgen, Bluebird Bio, BMS\/Celgene, Calibr, Cellular Biomedicine Group, Cowen, ecoR1, Emerging Therapy Solutions Gerson Lehman Group, GammaDelta Therapeutics, Iovance, Janssen, Kite, a Gilead Company, Legend Biotech, Novartis, Umoja and Wugen; research funding from Allogene, Kite and Novartis; and patents, royalties and other intellectual property in the field of cellular immunotherapy. S.F. reports employment and stock or ownership with Kite, a Gilead Company, and patents, royalties and other intellectual property from Tusk Therapeutics. J.C. reports employment with, leadership role in and travel support from Kyverna and Kite, a Gilead Company; stock or other ownership in Gilead Sciences; and research funding, patents, royalties and other intellectual property from Kite. S.V. reports employment with and research funding from Kite, a Gilead Company; and stock or other ownership in Gilead Sciences. R.P. reports employment and stock or other ownership with Veracyte. P.D. reports a consulting or advisory role for, honoraria from and speakers\u2019 bureau participation for Bristol-Myers Squibb, Gilead Sciences and Novartis. B.T.H reports honoraria from, a consulting or advisory role for, research funding from and travel support from Kite, a Gilead Company. C.L. reports stock in Kadmon; honoraria from CareDX, Jazz, Kadmon and Kite, a Gilead Company; a consulting or advisory role for Fresenius Kabi; and research funding from Incyte. P.L.Z. reports a consultant role for MSD, Eusa Pharma and Novartis; speakers\u2019 bureau participation for Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Servier, MSD, TG Therapeutics, Takeda, Roche, Eusa Pharma, Kyowa Kirin, Novartis, Incyte, and Beigene; and advisory board participation for Secura Bio, Celltrion, Gilead Sciences, Janssen-Cilag, Bristol-Myers Squibb, Servier, Sandoz, MSD, TG Therapeutics, Takeda, Roche, Eusa Pharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte and Beigene. N.K. reports honoraria from and a consulting or advisory role for Kite, a Gilead Company; and research funding from Neovii, Novartis and Riemser. A.L.-G. reports a consulting or advisory role for Celgene, Incyte, Kite, a Gilead company, Novartis, Roche and Takeda; research funding from Celgene, Kite and Roche; and travel, accommodation and expenses from Kite. H.G. and W.Z. have no relevant financial relationships to disclose. G.T. and F.M.M. report employment with Kite, a Gilead Company. J.B., C.T., M.S. and H.M. report employment with Kite, a Gilead Company; and stock or other ownership in Gilead Sciences. M.M. and P.C. report employment with Kite, a Gilead Company, and patents, royalties and other intellectual property, and travel support from Kite; and stock or other ownership with Gilead Sciences. A.B. reports former employment with Kite, a Gilead Company; current employment and a leadership role with Capstan Therapeutics; stock or other ownership with Capstan Therapeutics and Gilead Sciences; a consulting or advisory role for Cero Therapeutics and Elicio; and expert testimony for Gilead Sciences. R.S. reports employment with and stock or other ownership in Kite, a Gilead Company; and patents, royalties and other intellectual property from Atara and Kite. D.B. reports employment with Kite, a Gilead Company. J.G. reports employment with Veracyte; a leadership role and consulting or advisory role in Northwest Biotherapeutics and Lunaphore; stock or other ownership in and travel support from Veracyte; research funding from Imcheck Therapeutics and Veracyte; and patents, royalties or other intellectual property from Inserm.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}